NNPA NEWSWIRE — Dr. Wally Smith’s tireless efforts are among the many reasons the National Newspaper Publishers Association (NNPA) awarded the physician with a 2018 National...
Dr. Kevin Williams, the chief medical officer for Rare Disease at Pfizer discusses the stigma associated with sickle cell disease, emergency room treatment for SCD patients,...
The NNPA will honor Senator Kamala Harris with the NNPA’s 2018 Newsmaker of the Year Award during Black Press Week. James Farmer, Rep. Barbara Lee of...
By Dr. Kevin Williams (Chief Medical Officer, Pfizer Rare Disease Unit) This article is the third installment in the “Ask Dr. Kevin” series, brought to you...
By Dr. Kevin Williams (Chief Medical Officer, Pfizer Rare Disease Unit) This article is the second installment in the “Ask Dr. Kevin” series, brought to you...
By Stacy M. Brown (NNPA Newswire Contributor) You really don’t know a company, until you know the people who work there. Those were the introductory words...
Ask Dr. Kevin is a new feature brought to you by Pfizer Rare Disease in collaboration with the National Newspaper Publishers Association (NNPA) to increase understanding...
By Stacy M. Brown (NNPA Newswire Contributor) Dr. Kevin Williams, the chief medical officer for Pfizer’s rare disease unit, plans to help educate the masses about...
Media Contacts: Steven Danehy 212-733-1538 Steven.Danehy@pfizer.com Claudette Perry 212-588-8764 Ext. 2 cperry@nnpa.org Collaboration Aims to Educate on the Importance of Clinical Trials in Developing Potential New...
By Joan H. Allen (NNPA News Wire Contributor) June 19, 2016 marks World Sickle Cell Day. In a desire to help create a greater awareness of...
(Tech Times) – Pfizer’s breast cancer drug Ibrance shows favorable clinical trial after facing delays due to efficacy issues. Ibrance is also well-known as palbociclib...
DANICA KIRKA, Associated Press LONDON (AP) — Pfizer Inc.’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses — but...
[Business Week] The long promise of insulin that diabetics can inhale appears to be moving closer to the market. An inhalable insulin powder called Afrezza showed...
[New York Times] She was a 32-year-old aerobics instructor from a Dallas suburb — healthy, college educated, with two young children. Nothing out of the ordinary,...
